Ovarian cancer vs Ovarian cyst benign
How to tell Ovarian cancer and Ovarian cyst benign apart when a board question makes them look alike.
Step 2 CK pairs are in open beta while clinical review finishes. Spot an issue? Tell us.
Complex solid adnexal morphology with ascites on transvaginal ultrasound is the key discriminator for ovarian cancer risk.
Side by side
Postmenopausal patient with complex solid adnexal mass, ascites, and elevated tumor marker profile is highly suspicious for ovarian malignancy.
Premenopausal patient with a simple thin-walled unilocular cyst and no malignant features is likely benign and often observed.
Epithelial ovarian malignancy grows with invasive peritoneal spread and ascites formation.
Functional benign cysts arise from ovulatory physiology and often regress spontaneously.
Suspicious imaging includes solid papillary components, septations, bilateral masses, or ascites; CA-125 above 35 U/mL in postmenopausal patients raises concern but is not diagnostic alone.
Benign simple cysts are usually anechoic, thin-walled, unilocular, and less than about 5 cm in premenopausal patients with stable follow-up imaging.
The trap
The common trap is relying on CA-125 alone to diagnose cancer in premenopausal patients. The resolving clue is ultrasound morphology and menopausal context, which drive referral urgency.
The repair move
Next best step: refer urgently to gynecologic oncology for staging laparotomy planning and tissue diagnosis rather than cyst observation. For low-risk simple cysts in premenopausal patients, use interval ultrasound surveillance, typically in 6 to 12 weeks, unless symptoms or morphology worsen.
Try a free question
CoreA postmenopausal woman has a complex bilateral adnexal mass with solid papillary projections and ascites on transvaginal ultrasound. What is the next best step in management?
Show answer and explanation
Answer: A. Urgent gynecologic oncology referral for staging and tissue diagnosis. High-risk adnexal morphology with ascites in a postmenopausal patient requires urgent oncologic evaluation.
Why the other choices are tempting
- B. Wrong because delayed surveillance risks progression in likely cancer.
- C. Wrong because hormonal suppression is not treatment for probable ovarian malignancy.
- D. Wrong because infectious treatment does not address complex neoplastic mass features.
- E. Wrong because no follow-up is unsafe for high-risk adnexal findings.
Flashcards
Tap a card to flip it.
Which ultrasound feature most strongly suggests ovarian malignancy instead of a benign cyst?
A complex adnexal mass with solid components and ascites strongly suggests malignancy.
Why is CA-125 alone insufficient to label an adnexal mass malignant?
CA-125 can rise in many benign conditions, especially in premenopausal patients, so imaging context is essential.
Quick answers
What is the fastest way to tell Ovarian cancer from Ovarian cyst benign?
Complex solid adnexal morphology with ascites on transvaginal ultrasound is the key discriminator for ovarian cancer risk.
What is the key clue for Ovarian cancer?
Postmenopausal patient with complex solid adnexal mass, ascites, and elevated tumor marker profile is highly suspicious for ovarian malignancy.
What is the key clue for Ovarian cyst benign?
Premenopausal patient with a simple thin-walled unilocular cyst and no malignant features is likely benign and often observed.
What is the common trap with Ovarian cancer vs Ovarian cyst benign?
The common trap is relying on CA-125 alone to diagnose cancer in premenopausal patients. The resolving clue is ultrasound morphology and menopausal context, which drive referral urgency.